Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology April 21, 2026
Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas April 21, 2026
Darlifarnib + Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell RCC Previously Treated With Cabozantinib April 21, 2026
FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer April 21, 2026
First US Site Activated for Ongoing International Ph 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced NSCLC April 21, 2026
Daraxonrasib Demonstrates Unprecedented OS Benefit in Ph 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer April 21, 2026
Supplemental BLA submitted to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma; Included in updated NCCN Guidelines April 21, 2026
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer April 21, 2026
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development April 21, 2026
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement April 21, 2026
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15 April 21, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform April 21, 2026
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Gen Dual-Payload ADCs April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Positive PDS01ADC Interim Ph 2 Trial Data from Stage 1 of NCI-led Metastatic CRC Trial Published April 21, 2026
Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Presented April 21, 2026
Ph 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) Presented April 21, 2026
Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts April 21, 2026
Promising Clinical Activity and Favorable Safety Profile Reported for ACE-106 in solid tumors April 21, 2026
KIMMTRAK doubles the 5-yr survival rate for 1L HLA-A*02:01+ patients with metastatic uveal melanoma April 21, 2026
Ph 2 trial of botensilimab (BOT), balstilimab (BAL) & agenT-797 in GEJ cancer shows 77% DCR and long-term survival beyond 20 months in heavily pretreated patients April 21, 2026
